Pulmonology

Severe asthma affects 5% to 10% of adults with asthma. Find out what you know about diagnosis and treatment options for these patients with 5 no-nonsense questions.

AHA 2020 Virtual Scientific Sessions: Cumulative exposure, exposure intensity, and number of household smokers in childhood all impact adult heart function, study authors found.

The novel monoclonal antibody could bring relief to millions of persons with severe, uncontrolled asthma, including those with a low eosinophil phenotype.

Use of the myCOPD app after hospitalization for acute COPD exacerbation reduced subsequent exacerbations by nearly 50%, according to study authors.

New research presented at the American Thoracic Society virtual symposium showed the first-in-class drug reduced severe asthma exacerbation rate by 35% vs placebo.

In COPD patients, a new study found no association between lung function decline and individual CVD outcomes, but disease exacerbations and dyspnea were implicated.

Mepolizumab (Nucala) received a new indication for the treatment of hypereosinophilic syndrome in patients aged ≥12 years.

More than 10% of those who develop severe COVID-19 have misguided antibodies that derail the immune response, according to new research.

Long-acting muscarinic antagonists, recommended as add-on therapy for asthma, are too often used as monotherapy and are linked with severe exacerbations, a new study finds.

Along with COPD, fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) is now approved for the treatment of asthma in patients aged ≥18 years.

New research presented at the virtual European Respiratory Society International Congress showed "social smokers" are more than twice as likely to die of lung disease vs non-smokers.

Treatment guidelines on COVID-19 from the NIH were updated today based on data from clinical trials of hydroxychloroquine, ivermectin, and IL-6 inhibitors.

The ACIP, once more, revised its recommendations for administration of pneumococcal vaccination among adults aged ≥65 years. Is there a lesson learned here?

A new survey found adolescents who have ever used e-cigarettes are 5-times more likely to receive a COVID-19 diagnosis. More results at-a-glance in our new slideshow.

The investigational antiviral remdesivir in phase 3 clinical trials led to faster time to recovery vs placebo and was found to be safe.

A new survey suggests use of e-cigarettes and dual use of e-cigarettes and traditional cigarettes are significant underlying risk factors for COVID-19 among US adolescents.

New research presented at the American Thoracic Society 2020 Virtual meeting showed the novel Theraflu Home FluTest demonstrated good sensitivity and specificity for influenza A and B viruses.

New research presented at the ATS 2020 Virtual meeting shows adolescents who use e-cigarettes along with marijuana and/or cigarette smoking have significantly higher odds of lifetime asthma.

Patient's vital signs and results of physical examination are normal; results of a previous lumbar puncture also were normal. What does the chest x-ray reveal?

Approval was awarded to AstraZeneca for an inhaled, fixed-dose combination of budesonide/glycopyrrolate/formoterol fumarate.

JAMA: After recovery from COVID-19, a majority of patients reported persistence of at least 1 symptom; more than half reported ≥3 symptoms.

The proposed recommendations will allow more women and black patients to be eligible for lung cancer screening.

Prolonged "air hunger" induced during mechanical ventilation for severe COVID-19 infection can be eliminated by a change in standard of care, a new paper suggests.

Adherence to controller medication appears to have increased between early January and late March among patients with asthma and COPD, finds a new study.

Try your hand at these 8 questions based on the latest CDC guidance on rehospitalization and mortality in patients with vaping-related lung injury.